Lupin Launches Paliperidone Extended-Release Tablets in the United States

Global pharma major Lupin Limited (Lupin) has announced the launch of Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg and 9 mg, to market a generic equivalent of Invega® Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg and 9 mg, of Janssen Research and Development, LLC.

Paliperidone Extended-Release Tablets (RLD Invega®) had estimated annual sales of USD 112 million in the U.S. (IQVIA MAT August 2022).

Shares of Lupin Limited was last trading in BSE at Rs. 678.90 as compared to the previous close of Rs. 688.10. The total number of shares traded during the day was 96524 in over 1922 trades.

The stock hit an intraday high of Rs. 691.00 and intraday low of 670.65. The net turnover during the day was Rs. 65869069.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Launch Paliperidone ExtendedRelease Tablets